Boundless Bio Stock

boundlessbio.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $252.05MM

Boundless Bio, founded in 2018, is a biopharmaceutical company that develops novel cancer therapeutics seeking to understand and treat intractable cancers. Boundless Bio aims to interrogate extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers. Boundless Bio is headquartered in La Jolla, California.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Boundless Bio before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Boundless Bio before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Boundless Bio stock FAQs

plusminus

Can you buy Boundless Bio stock?

You can no longer buy Boundless Bio stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Boundless Bio stock?

To invest in a private company like Boundless Bio through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Boundless Bio stock?

You can no longer sell stock of Boundless Bio on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Boundless Bio stock?

If you hold private company shares of Boundless Bio - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Boundless Bio stock on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Boundless Bio a public company?

No, Boundless Bio is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Boundless Bio’s stock ticker symbol?

The ticker symbol of Boundless Bio is BOLD.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Boundless Bio investors also invested in these private companies

Cambridge Innovation Capital
Sectoral Asset Management
National Cancer Institute
City Hill Ventures
Tavistock Group
PFM Health Sciences
GT Healthcare Capital Partners
Citadel Enterprise Americas

Team

Management Team

Zachary Hornby
Chief Executive Officer & President
Christian Hassig Ph.D
Chief Scientific Officer
Neil Abdollahian
Chief Business Officer
Jonathan Lim MD
Co-Founder
Benjamin Cravatt Ph.D
Co-Founder
Klaus Wagner Ph.D
Chief Medical Officer

Board Members

Christine Brennan Ph.D
Vertex Ventures HC
Fabio Pucci Ph.D
RA Capital Management
Kristina Burow
ARCH Venture Partners
Boundless Bio, the precision oncology company working on treatments for oncogene-amplified cancers, is amping up its fundraising with a new $100 million series C round backed by Leaps by Bayer and RA Capital Management.
Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancer, today announced that the first patient has been dosed with BBI-355 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors with oncogene amplifications (NCT05827614).
Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.